ArticleDevelopmental neurobiology2026
Maternal and Postnatal Effects of Poly I:C-Induced Intrauterine Inflammation and Rytvela, a Non-Competitive IL-1R Antagonist, in the Pregnant Spiny Mouse.
Article in Developmental neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Maternal and Postnatal Effects of Poly I:C-Induced Intrauterine Inflammation and Rytvela, a Non-Competitive IL-1R Antagonist, in the Pregnant Spiny Mouse.Developmental neurobiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Maternal infection-induced inflammation during pregnancy is associated with adverse neurodevelopment. Rytvela, an allosteric IL-1 receptor antagonist, reduces IL-1β-mediated pathology in fetal rodents and sheep. However, its effects on TLR3-mediated inflammation and subsequent offspring growth and behavior remain unclear. Using precocial spiny mice, the primary outcome of this study was to examine whether rytvela could attenuate the acute maternal inflammatory response to mid-gestation exposure to polyinosinic:polycytidylic acid (Poly(I:C)). Secondary offspring outcomes included postnatal growth and behavior. At gestational day 20 (term = 39 days), pregnant mice received two intraperitoneal injections, 4 h apart, of saline (0.9% w/v, n = 14), Poly(I:C) (12 mg/kg, n = 14), or Poly(I:C) + rytvela (12 mg/kg + 3 mg/kg, respectively, n = 14). Ten dams/group were culled 8 h after dose 1 to assess inflammatory responses. The remainder (n = 4 dams/group) were delivered at term. Offspring (control n = 7, Poly(I:C) n = 8, Poly(I:C) + rytvela n = 11) growth was monitored and behavioral testing undertaken from postnatal day (PND) 3-45. Poly(I:C) increased maternal serum (p = 0.01) and amniotic fluid (p = 0.003) IL-1β, and upregulated Il1b, Il6 and Tnf expression in the spleen and thymus. Rytvela reduced IL-1β levels but did not attenuate elevated cytokine gene expression. Poly(I:C) slowed postnatal growth (PND 18-27, p < 0.05), which recovered earlier with rytvela. Poly(I:C) exposure did not alter offspring behavior in tests completed to PND 45. However, Poly(I:C) + rytvela offspring showed reduced locomotor activity (distance: p < 0.001; velocity: p = 0.021). In conclusion, rytvela attenuated the primary inflammatory response to Poly(I:C), promoting earlier postnatal growth recovery despite persistent cytokine gene expression. Reduced locomotor activity after prenatal rytvela exposure warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.